Phase 1 Study of Everolimus in Combination With Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2017
At a glance
- Drugs Brentuximab vedotin (Primary) ; Everolimus (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions
- 18 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 16 Mar 2017 Status changed from suspended to recruiting.
- 08 Feb 2016 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.